<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Tirzepatide: what changed | Grey Peptides</title>
    <link>https://greypeptides.com/changes/#e-tirzepatide</link>
    <atom:link href="https://greypeptides.com/changes/tirzepatide.xml" rel="self" type="application/rss+xml" />
    <description>News, regulatory alerts, corrections and new guides about Tirzepatide on Grey Peptides, newest first.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 18 Nov 2026 12:00:00 +0000</lastBuildDate>
    <ttl>1440</ttl>
    <item>
      <title>New guide: What lab testing shows</title>
      <link>https://greypeptides.com/testing/#c-tirzepatide</link>
      <guid isPermaLink="false">greypeptides-changes-tirzepatide-guide-/testing/#c-tirzepatide</guid>
      <pubDate>Wed, 18 Nov 2026 12:00:00 +0000</pubDate>
      <category>New guide</category>
      <description>The largest analysis of grey-market test results (a preprint): purity, amount, identity and endotoxin.</description>
    </item>
    <item>
      <title>News: How Many Americans Take a GLP-1? What Gallup's Surveys Actually Say</title>
      <link>https://greypeptides.com/news/gallup-glp1-use-us-adults-2026/</link>
      <guid isPermaLink="false">greypeptides-changes-tirzepatide-news-gallup-glp1-use-us-adults-2026</guid>
      <pubDate>Wed, 04 Nov 2026 12:00:00 +0000</pubDate>
      <category>News</category>
      <description>How Many Americans Take a GLP-1? What Gallup's Surveys Actually Say</description>
    </item>
    <item>
      <title>News: Berobenatide: Pfizer's Monthly GLP-1 Peptide Is Now in Eleven Phase 3 Trials</title>
      <link>https://greypeptides.com/news/berobenatide-phase-3-vesper-programme/</link>
      <guid isPermaLink="false">greypeptides-changes-tirzepatide-news-berobenatide-phase-3-vesper-programme</guid>
      <pubDate>Wed, 04 Nov 2026 12:00:00 +0000</pubDate>
      <category>News</category>
      <description>Berobenatide: Pfizer's Monthly GLP-1 Peptide Is Now in Eleven Phase 3 Trials</description>
    </item>
    <item>
      <title>News: VK2735: Viking Starts Its Oral Phase 3 Trials and Reports Less-Frequent Maintenance Dosing</title>
      <link>https://greypeptides.com/news/vk2735-sunrise-oral-phase-3-maintenance/</link>
      <guid isPermaLink="false">greypeptides-changes-tirzepatide-news-vk2735-sunrise-oral-phase-3-maintenance</guid>
      <pubDate>Tue, 03 Nov 2026 12:00:00 +0000</pubDate>
      <category>News</category>
      <description>VK2735: Viking Starts Its Oral Phase 3 Trials and Reports Less-Frequent Maintenance Dosing</description>
    </item>
    <item>
      <title>News: CagriSema Against Tirzepatide in Type 2 Diabetes: What REIMAGINE 5 Shows</title>
      <link>https://greypeptides.com/news/reimagine-5-cagrisema-vs-tirzepatide/</link>
      <guid isPermaLink="false">greypeptides-changes-tirzepatide-news-reimagine-5-cagrisema-vs-tirzepatide</guid>
      <pubDate>Wed, 07 Oct 2026 12:00:00 +0000</pubDate>
      <category>News</category>
      <description>CagriSema Against Tirzepatide in Type 2 Diabetes: What REIMAGINE 5 Shows</description>
    </item>
    <item>
      <title>News: EloraTZP Phase 2b: 23.3% Weight Loss in Type 2 Diabetes, and Up to 27% Stopped for Side Effects</title>
      <link>https://greypeptides.com/news/eloratzp-phase-2b-type-2-diabetes/</link>
      <guid isPermaLink="false">greypeptides-changes-tirzepatide-news-eloratzp-phase-2b-type-2-diabetes</guid>
      <pubDate>Fri, 02 Oct 2026 12:00:00 +0000</pubDate>
      <category>News</category>
      <description>EloraTZP Phase 2b: 23.3% Weight Loss in Type 2 Diabetes, and Up to 27% Stopped for Side Effects</description>
    </item>
    <item>
      <title>Regulatory alert: US FDA: FDA warned a Houston compounding pharmacy that its tirzepatide with niacinamide and semaglutide with vitamin B12 appear to be essentially copies of approved GLP-1 drugs, made in volumes suggesting the added vitamin is pretextual. Posted September 22.</title>
      <link>https://greypeptides.com/regulatory/alerts/#fda-wl-vitamin-glp1-copies</link>
      <guid isPermaLink="false">greypeptides-changes-tirzepatide-alert-fda-wl-vitamin-glp1-copies</guid>
      <pubDate>Fri, 18 Sep 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>Adding a vitamin does not by itself make a compounded GLP-1 lawful. The statute's condition is a prescriber's documented, patient-specific significant difference; pre-written prescriber determinations were part of FDA's case.</description>
    </item>
    <item>
      <title>Regulatory alert: Netherlands (IGJ): The Dutch health inspectorate imposed a penalty order on the online seller it had ordered on August 24 to stop selling retatrutide, tirzepatide and semaglutide, after the seller kept selling.</title>
      <link>https://greypeptides.com/regulatory/alerts/#igj-penalty-order-online-seller</link>
      <guid isPermaLink="false">greypeptides-changes-tirzepatide-alert-igj-penalty-order-online-seller</guid>
      <pubDate>Mon, 31 Aug 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>Dutch enforcement moved from an order to escalating penalties within a week. Retatrutide is approved nowhere, and the two approved GLP-1s are prescription medicines that a webshop may not supply.</description>
    </item>
    <item>
      <title>Regulatory alert: Netherlands (IGJ): The Dutch health inspectorate ordered an online webshop trading under several names to end the supply, delivery and trade of medicines containing retatrutide, tirzepatide and semaglutide.</title>
      <link>https://greypeptides.com/regulatory/alerts/#igj-order-online-seller</link>
      <guid isPermaLink="false">greypeptides-changes-tirzepatide-alert-igj-order-online-seller</guid>
      <pubDate>Mon, 24 Aug 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>In the EU, selling these as 'peptides' online does not take them outside medicines law; the inspectorate treats them as medicines supplied without the required licences.</description>
    </item>
    <item>
      <title>Regulatory alert: US FDA: FDA sent warning letters to five online peptide sellers in North Carolina, Florida, Texas and Arizona, calling retatrutide, semaglutide, tirzepatide and other peptides unapproved new drugs. Posted September 1.</title>
      <link>https://greypeptides.com/regulatory/alerts/#fda-wl-five-online-sellers</link>
      <guid isPermaLink="false">greypeptides-changes-tirzepatide-alert-fda-wl-five-online-sellers</guid>
      <pubDate>Mon, 24 Aug 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>A 'research use only' label did not decide the case: FDA read intended use from the whole website. Selling bacteriostatic water and offering a peptide calculator counted as evidence of human use.</description>
    </item>
    <item>
      <title>Regulatory alert: US FDA: FDA extended the comment period on its proposal not to put semaglutide, tirzepatide or liraglutide on the 503B bulks list by 30 days, to July 30, 2026 (91 FR 38719).</title>
      <link>https://greypeptides.com/regulatory/alerts/#503b-glp1-comment-extended</link>
      <guid isPermaLink="false">greypeptides-changes-tirzepatide-alert-503b-glp1-comment-extended</guid>
      <pubDate>Fri, 26 Jun 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>Comments are closed. As of November 2, 2026 the Federal Register held no final determination: the June 26 extension is the newest document in docket FDA-2018-N-3240.</description>
    </item>
    <item>
      <title>News: A Single Peptide That Hits Five Receptors: The Quintuple Agonist</title>
      <link>https://greypeptides.com/news/quintuple-agonist-peptide-conjugate-nature/</link>
      <guid isPermaLink="false">greypeptides-changes-tirzepatide-news-quintuple-agonist-peptide-conjugate-nature</guid>
      <pubDate>Fri, 08 May 2026 12:00:00 +0000</pubDate>
      <category>News</category>
      <description>A Single Peptide That Hits Five Receptors: The Quintuple Agonist</description>
    </item>
    <item>
      <title>Regulatory alert: US FDA: FDA warned a Chinese maker of peptide ingredients, including semaglutide and tirzepatide, over manufacturing-quality failures and relabelling semaglutide bought from other suppliers as its own. It had been put on Import Alert 66-40 and removed from the Import Alert 66-80 Green List on February 27. Posted May 19.</title>
      <link>https://greypeptides.com/regulatory/alerts/#fda-wl-peptide-api-maker</link>
      <guid isPermaLink="false">greypeptides-changes-tirzepatide-alert-fda-wl-peptide-api-maker</guid>
      <pubDate>Fri, 01 May 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>The quality problem FDA describes sits upstream of any vial: the ingredient, and who really made it. Compounders depend on that ingredient, and 503A pharmacies are exempt from the manufacturing rules that would catch it.</description>
    </item>
    <item>
      <title>Regulatory alert: US FDA: FDA proposed not to include semaglutide, tirzepatide or liraglutide on the 503B bulks list (91 FR 23431, docket FDA-2018-N-3240).</title>
      <link>https://greypeptides.com/regulatory/alerts/#503b-glp1-proposal</link>
      <guid isPermaLink="false">greypeptides-changes-tirzepatide-alert-503b-glp1-proposal</guid>
      <pubDate>Fri, 01 May 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>A proposal, not a rule. It concerns outsourcing facilities compounding from bulk when there is no shortage; the three were never on the list, so nothing was removed.</description>
    </item>
    <item>
      <title>Regulatory alert: US FDA: FDA warned an outsourcing facility making tirzepatide and semaglutide after inspectors recovered mould during a tirzepatide run and found products released despite microbial recoveries.</title>
      <link>https://greypeptides.com/regulatory/alerts/#fda-wl-503b-mould</link>
      <guid isPermaLink="false">greypeptides-changes-tirzepatide-alert-fda-wl-503b-mould</guid>
      <pubDate>Tue, 07 Apr 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>Even regulated compounders fail sterility; the firm had recalled multidose vials. A grey-market vial has no inspection at all before it ships.</description>
    </item>
    <item>
      <title>Regulatory alert: US FDA: FDA warned two online sellers, in California and Arizona, that retatrutide, tirzepatide, semaglutide, cagrilintide and mazdutide, sold under code names such as 'GLP-1-R peptide' and 'GLP1-T', are unapproved new drugs. Posted April 7.</title>
      <link>https://greypeptides.com/regulatory/alerts/#fda-wl-two-online-sellers-march</link>
      <guid isPermaLink="false">greypeptides-changes-tirzepatide-alert-fda-wl-two-online-sellers-march</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>The code names did not hide the drugs, and 'laboratory research purposes only' labels did not change FDA's finding. Bacteriostatic water sold alongside was again part of the evidence.</description>
    </item>
    <item>
      <title>Regulatory alert: US FDA: FDA warned a state-licensed compounding pharmacy that released products, including a compounded tirzepatide injection, among nine lots that failed sterility testing.</title>
      <link>https://greypeptides.com/regulatory/alerts/#fda-wl-503a-sterility</link>
      <guid isPermaLink="false">greypeptides-changes-tirzepatide-alert-fda-wl-503a-sterility</guid>
      <pubDate>Fri, 16 Jan 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>A compounded GLP-1 is only as safe as the pharmacy's sterile practice; checking that a pharmacy is licensed and has no recent FDA letter is part of choosing one.</description>
    </item>
    <item>
      <title>Regulatory alert: US FDA: FDA launched a 'Green List' import alert (66-80): GLP-1 ingredients such as semaglutide and tirzepatide from foreign sites it has not found compliant can be detained without physical examination.</title>
      <link>https://greypeptides.com/regulatory/alerts/#fda-glp1-green-list</link>
      <guid isPermaLink="false">greypeptides-changes-tirzepatide-alert-fda-glp1-green-list</guid>
      <pubDate>Fri, 05 Sep 2025 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>It is aimed at ingredients for compounding, not at personal parcels: ingredients from sites on the Green List can still be imported.</description>
    </item>
    <item>
      <title>Regulatory alert: US FDA: FDA's enforcement discretion for outsourcing facilities compounding tirzepatide ended.</title>
      <link>https://greypeptides.com/regulatory/alerts/#503b-tirzepatide-discretion-ends</link>
      <guid isPermaLink="false">greypeptides-changes-tirzepatide-alert-503b-tirzepatide-discretion-ends</guid>
      <pubDate>Wed, 19 Mar 2025 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>Outsourcing facilities lost the shortage-era route to compounding tirzepatide.</description>
    </item>
    <item>
      <title>Regulatory alert: US FDA: FDA's enforcement discretion for 503A pharmacies compounding tirzepatide copies ended when a court denied a preliminary injunction.</title>
      <link>https://greypeptides.com/regulatory/alerts/#503a-tirzepatide-discretion-ends</link>
      <guid isPermaLink="false">greypeptides-changes-tirzepatide-alert-503a-tirzepatide-discretion-ends</guid>
      <pubDate>Wed, 05 Mar 2025 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>State-licensed pharmacies lost the routine route to compounding tirzepatide first.</description>
    </item>
  </channel>
</rss>
